Date
Attendees
Richard Norman (Unlicensed) (Pistoia Alliance)
Francisco Fernandez (Deactivated) (Abvance Biotech)
- Bryan Jones (Deactivated) (Eli Lilly)
- Chris Lloyd (Deactivated) (MedImmune)
- Carmen Nitsche (Deactivated) (Pistoia Alliance)
- Abhinandan Raghavan (Deactivated) (Novartis)
- Kieran Todd (Deactivated) (GSK)
Agenda
| Time | Item | Who | Output |
|---|---|---|---|
| 17:00 - 18:00 (60 mins) | >Value proposition and ‘sliding-scale scenarios’ for top level management proposal. >Sign up on IP3. | Richard, All | >Agree value proposition and draft scenarios for top level management
|
| If time permits | >EMBL-EBI presentation outline. |
Minutes
Scope
>We should distinguish between early screening (high throughput) and profiling (detailed, low-throughput) assays even though both are included in the scope. Expectation is there will be more data points for early screening vs. profiling assays.
...